Hologic (HOLX) Expected to Announce Quarterly Earnings on Wednesday

Hologic (NASDAQ:HOLX) will likely be announcing its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $1.02 per share and revenue of $1.02 billion for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.89 EPS. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Stock Down 0.0 %

Shares of NASDAQ:HOLX opened at $72.14 on Monday. The company has a market capitalization of $16.28 billion, a PE ratio of 21.66, a P/E/G ratio of 2.33 and a beta of 0.97. Hologic has a 52 week low of $68.61 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company’s fifty day moving average is $73.35 and its 200-day moving average is $78.07.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HOLX. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada lifted their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Wolfe Research began coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Leerink Partners cut their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Mizuho decreased their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.